Related content

Reply to Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery?

By Maru Dipen M.   Agarwal Atin A.   Hu Chung-Yuan   Chang George J.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1282-1282

Blackwell Publishing

Access to resources Recommend Favorite

Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation

By Gordon Michael A   Gil Ji   Lu Bo   Zhang Wu   Yang Dongyun   Yun Jim   Schneider Sylke   Groshen Susan   Iqbal Syma   Press Oliver A   Rhodes Katrin   Lenz Heinz-Josef  

Pharmacogenomics, Vol. 7, Iss. 1, 2006-01 ,pp. : 67-88

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response

By Balboa Emilia   Duran Goretti   Lamas Maria Jesus   Gomez-Caamaño Antonio   Celeiro-Muñoz Catuxa   Lopez Rafael   Carracedo Angel   Barros Francisco  

Pharmacogenomics, Vol. 11, Iss. 6, 2010-06 ,pp. : 747-761

Future Medicine

Access to resources Recommend Favorite

The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer

By Abern Michael R.   Terris Martha K.   Aronson William J.   Kane Christopher J.   Amling Christopher L.   Cooperberg Matthew R.   Freedland Stephen J.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1656-1662

Blackwell Publishing

Access to resources Recommend Favorite

Chromosomal instability portends superior response of rectal adenocarcinoma to chemoradiation therapy

By Zaki Bassem I.   Suriawinata Arief A.   Eastman Alan R.   Garner Kristen M.   Bakhoum Samuel F.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1733-1742

Blackwell Publishing

Access to resources Recommend Favorite